Positive News SentimentPositive NewsNASDAQ:BLTE Belite Bio (BLTE) Stock Price, News & Analysis $65.13 +1.51 (+2.37%) Closing price 08/26/2025 04:00 PM EasternExtended Trading$65.79 +0.66 (+1.01%) As of 08/26/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Belite Bio Stock (NASDAQ:BLTE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Belite Bio alerts:Sign Up Key Stats Today's Range$64.40▼$67.4150-Day Range$56.81▼$72.7352-Week Range$43.70▼$86.53Volume28,046 shsAverage Volume49,736 shsMarket Capitalization$2.07 billionP/E RatioN/ADividend YieldN/APrice Target$96.67Consensus RatingBuy Company Overview Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd. Read More Belite Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreBLTE MarketRank™: Belite Bio scored higher than 60% of companies evaluated by MarketBeat, and ranked 623rd out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBelite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBelite Bio has only been the subject of 1 research reports in the past 90 days.Read more about Belite Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Belite Bio are expected to grow in the coming year, from ($1.17) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Belite Bio is -42.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Belite Bio is -42.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBelite Bio has a P/B Ratio of 13.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Belite Bio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.61% of the float of Belite Bio has been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Belite Bio has recently decreased by 2.87%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBelite Bio does not currently pay a dividend.Dividend GrowthBelite Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.61% of the float of Belite Bio has been sold short.Short Interest Ratio / Days to CoverBelite Bio has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Belite Bio has recently decreased by 2.87%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News SentimentN/A News SentimentBelite Bio has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.98 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Belite Bio this week, compared to 3 articles on an average week.Search Interest2 people have searched for BLTE on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Belite Bio insiders have not sold or bought any company stock.Percentage Held by Insiders13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.53% of the stock of Belite Bio is held by institutions.Read more about Belite Bio's insider trading history. Receive BLTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BLTE Stock News HeadlinesBelite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual ConferenceAugust 13, 2025 | theglobeandmail.comBelite Bio’s Earnings Call: Progress Amid ChallengesAugust 13, 2025 | msn.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes. | Porter & Company (Ad)Belite Bio, Inc (BLTE) Q2 2025 Earnings Call TranscriptAugust 11, 2025 | seekingalpha.comBelite Bio, Inc 2025 Q2 - Results - Earnings Call PresentationAugust 11, 2025 | seekingalpha.comBelite Bio, Inc: Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateAugust 11, 2025 | finanznachrichten.deBelite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateAugust 11, 2025 | globenewswire.com1BLTE : Belite Bio's Earnings OutlookAugust 8, 2025 | benzinga.comSee More Headlines BLTE Stock Analysis - Frequently Asked Questions How have BLTE shares performed this year? Belite Bio's stock was trading at $63.10 on January 1st, 2025. Since then, BLTE shares have increased by 3.2% and is now trading at $65.13. How were Belite Bio's earnings last quarter? Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) released its quarterly earnings data on Monday, August, 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by $0.03. Read the conference call transcript. When did Belite Bio IPO? Belite Bio (BLTE) raised $36 million in an initial public offering on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share. Who are Belite Bio's major shareholders? Belite Bio's top institutional shareholders include Marshall Wace LLP (0.03%), JPMorgan Chase & Co. (0.02%), BNP Paribas Financial Markets (0.01%) and EverSource Wealth Advisors LLC (0.01%). How do I buy shares of Belite Bio? Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Belite Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Belite Bio investors own include Paycom Software (PAYC), Centrus Energy (LEU), Planet Labs PBC (PL), uniQure (QURE), Grayscale Ethereum Trust (ETH) (ETHE), Marathon Oil (MRO) and Vale (VALE). Company Calendar Last Earnings8/11/2025Today8/27/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BLTE CIK1889109 Webbelitebio.com Phone858-246-6240FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Belite Bio$96.67 High Price Target$110.00 Low Price Target$80.00 Potential Upside/Downside+48.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.14 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.90% Return on Assets-33.56% Debt Debt-to-Equity RatioN/A Current Ratio23.15 Quick Ratio23.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book13.83Miscellaneous Outstanding Shares31,840,000Free Float27,607,000Market Cap$2.07 billion OptionableNot Optionable Beta-1.49 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:BLTE) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredChase, Bank of America, Wells Fargo Preparing for BIG ChangeThanks to this brand-new law #S.1582 signed by President Trump… Jeff Brown believes the largest banks in Am...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.